- Page 1 and 2: Immunotherapy for Infectious Diseas
- Page 3 and 4: In f e c t i o u s . D i s e a s e
- Page 5 and 6: © 2002 Humana Press Inc. 999 River
- Page 7 and 8: vi Preface I am grateful to all of
- Page 9 and 10: viii Contents 11 Passive Immunother
- Page 11: x Contributors BARBARA G. MATTHEWS,
- Page 15 and 16: 4 Nara Erlich introduced a number o
- Page 17 and 18: 6 Nara Fig. 2. Immunoglobulin struc
- Page 19 and 20: 8 Nara Table 2 Receptors for the Co
- Page 21 and 22: 10 Nara Fig. 4. Primary (dotted lin
- Page 23 and 24: 12 Nara Fig. 5. Diagram showing how
- Page 25 and 26: 14 Nara Fig. 8. Macrophages with cl
- Page 27 and 28: 16 Nara against disease at the leve
- Page 29 and 30: 18 Nara excluded from follicles are
- Page 31 and 32: 20 Nara 6. Seledtsov VI, Seledtsova
- Page 33 and 34: 22 Nara 52. Chen ZJ, Wheeler CJ, Sh
- Page 35 and 36: 24 Bucy and Goepfert Fig. 1. Two pa
- Page 37 and 38: 26 Bucy and Goepfert rates of HIV-1
- Page 39 and 40: 28 Bucy and Goepfert Fig. 2. Multip
- Page 41 and 42: 30 Bucy and Goepfert the continual
- Page 43 and 44: 32 Bucy and Goepfert tion may be cr
- Page 45 and 46: 34 Bucy and Goepfert responses duri
- Page 47 and 48: 36 Bucy and Goepfert 36. Weaver CT,
- Page 49 and 50: 38 Bucy and Goepfert siveness in th
- Page 51 and 52: 40 Boyaka and McGhee (BALT) (3) wer
- Page 53 and 54: 42 Boyaka and McGhee Lymphocyte Hom
- Page 55 and 56: 44 Boyaka and McGhee S-PLA2 are als
- Page 57 and 58: 46 Boyaka and McGhee mechanisms. Fo
- Page 59 and 60: 48 Boyaka and McGhee subunits (133,
- Page 61 and 62: 50 Boyaka and McGhee Immunostimulat
- Page 63 and 64:
52 Boyaka and McGhee 16. Lebman DA,
- Page 65 and 66:
54 Boyaka and McGhee 54. Zabel BA,
- Page 67 and 68:
56 Boyaka and McGhee 95. Beagley KW
- Page 69 and 70:
58 Boyaka and McGhee 133. Gill DM.
- Page 71 and 72:
60 Boyaka and McGhee 172. Mowat AM,
- Page 74 and 75:
Production of Immunoglobulins and M
- Page 76 and 77:
Production of Igs and MAbs Targetin
- Page 78 and 79:
Production of Igs and MAbs Targetin
- Page 80 and 81:
Production of Igs and MAbs Targetin
- Page 82 and 83:
71 Table 2 Summary of Favorable Fun
- Page 84 and 85:
73 Fig. 7. Technologies for stable
- Page 86 and 87:
Production of Igs and MAbs Targetin
- Page 88 and 89:
Production of Igs and MAbs Targetin
- Page 90 and 91:
Production of Igs and MAbs Targetin
- Page 92 and 93:
Production of Igs and MAbs Targetin
- Page 94 and 95:
Production of Igs and MAbs Targetin
- Page 96 and 97:
Production of Igs and MAbs Targetin
- Page 98 and 99:
Production of Igs and MAbs Targetin
- Page 100 and 101:
Production of Igs and MAbs Targetin
- Page 102 and 103:
Production of Igs and MAbs Targetin
- Page 104 and 105:
Production of Igs and MAbs Targetin
- Page 106 and 107:
Production of Igs and MAbs Targetin
- Page 108:
Production of Igs and MAbs Targetin
- Page 111 and 112:
100 Kundu-Raychaudhuri and Engleman
- Page 113 and 114:
102 Kundu-Raychaudhuri and Engleman
- Page 115 and 116:
104 Kundu-Raychaudhuri and Engleman
- Page 117 and 118:
106 Kundu-Raychaudhuri and Engleman
- Page 119 and 120:
108 Kundu-Raychaudhuri and Engleman
- Page 121 and 122:
110 Kundu-Raychaudhuri and Engleman
- Page 123 and 124:
112 Kundu-Raychaudhuri and Engleman
- Page 125 and 126:
114 Kundu-Raychaudhuri and Engleman
- Page 127 and 128:
116 Kundu-Raychaudhuri and Engleman
- Page 129 and 130:
118 Matthews Cytokines can target a
- Page 131 and 132:
120 Matthews Table 1 Source and Act
- Page 133 and 134:
122 Matthews The Jak-Stat Model of
- Page 135 and 136:
124 Matthews and heart. Interesting
- Page 137 and 138:
126 Matthews In humans, Th1 cells p
- Page 139 and 140:
128 Matthews 20. Taub DD, Oppenheim
- Page 141 and 142:
130 Bona The immune system is compo
- Page 143 and 144:
132 Bona Fig. 2. Intracellular mech
- Page 145 and 146:
134 Bona Subunit Vaccines Subunit v
- Page 147 and 148:
136 Bona Table 4 Live Attenuated Va
- Page 149 and 150:
138 Bona Recombinant Vectors Vaccin
- Page 151 and 152:
140 Bona Table 6 DNA Vaccines Used
- Page 153 and 154:
142 Bona Fig. 3. Mechanisms of acti
- Page 155 and 156:
144 Bona Fig. 5. Mechanism of gener
- Page 157 and 158:
146 Bona Fig. 7. Structure of self
- Page 160:
III Immunotherapy for HIV Infection
- Page 163 and 164:
152 Fox Scope of the Epidemic World
- Page 165 and 166:
154 Fox receptor binding by the V3
- Page 167 and 168:
156 Fox plasma cells. Failure of th
- Page 169 and 170:
158 Fox Challenges of Therapeutic T
- Page 171 and 172:
160 Fox REFERENCES 1. UNAIDS. Repor
- Page 174 and 175:
INTRODUCTION Immune Reconstitution
- Page 176 and 177:
Immune Reconstitution with Antiretr
- Page 178 and 179:
Immune Reconstitution with Antiretr
- Page 180 and 181:
Immune Reconstitution with Antiretr
- Page 182 and 183:
Immune Reconstitution with Antiretr
- Page 184 and 185:
Immune Reconstitution with Antiretr
- Page 186 and 187:
Immune Reconstitution with Antiretr
- Page 188 and 189:
Immune Reconstitution with Antiretr
- Page 190:
Immune Reconstitution with Antiretr
- Page 193 and 194:
182 Kalams model, immune control is
- Page 195 and 196:
184 Kalams complexed with HLA class
- Page 197 and 198:
186 Kalams caused by an increase in
- Page 199 and 200:
188 Kalams series of treatment inte
- Page 201 and 202:
190 Kalams Another promising approa
- Page 203 and 204:
192 Kalams 29. Brander C, Hartman K
- Page 205 and 206:
194 Kalams 66. Altfeld M, Rosenberg
- Page 207 and 208:
196 Kalams virus infection. Militar
- Page 210 and 211:
INTRODUCTION From: Immunotherapy fo
- Page 212 and 213:
Passive Immunotherapy for HIV Infec
- Page 214 and 215:
Passive Immunotherapy for HIV Infec
- Page 216 and 217:
Passive Immunotherapy for HIV Infec
- Page 218 and 219:
Passive Immunotherapy for HIV Infec
- Page 220 and 221:
Passive Immunotherapy for HIV Infec
- Page 222 and 223:
Passive Immunotherapy for HIV Infec
- Page 224 and 225:
Passive Immunotherapy for HIV Infec
- Page 226 and 227:
Passive Immunotherapy for HIV Infec
- Page 228 and 229:
Passive Immunotherapy for HIV Infec
- Page 230 and 231:
Passive Immunotherapy for HIV Infec
- Page 232 and 233:
From: Immunotherapy for Infectious
- Page 234 and 235:
Host Cell-Directed Approaches 223 C
- Page 236 and 237:
Host Cell-Directed Approaches 225 s
- Page 238 and 239:
Host Cell-Directed Approaches 227 a
- Page 240 and 241:
Host Cell-Directed Approaches 229 t
- Page 242 and 243:
Host Cell-Directed Approaches 231 R
- Page 244 and 245:
Host Cell-Directed Approaches 233 4
- Page 246 and 247:
Host Cell-Directed Approaches 235 8
- Page 248 and 249:
INTRODUCTION From: Immunotherapy fo
- Page 250 and 251:
Gene Therapy for HIV-1 Infection 23
- Page 252 and 253:
Gene Therapy for HIV-1 Infection 24
- Page 254 and 255:
Gene Therapy for HIV-1 Infection 24
- Page 256 and 257:
Gene Therapy for HIV-1 Infection 24
- Page 258 and 259:
Gene Therapy for HIV-1 Infection 24
- Page 260:
IV Immunotherapy for Infectious Dis
- Page 263 and 264:
252 Onorato and Pollard However, th
- Page 265 and 266:
254 Onorato and Pollard patients wi
- Page 267 and 268:
256 Onorato and Pollard Another imm
- Page 269 and 270:
258 Onorato and Pollard 26. Guidott
- Page 271 and 272:
260 Sili, Heslop, and Rooney Fig. 1
- Page 273 and 274:
262 Sili, Heslop, and Rooney Fig. 2
- Page 275 and 276:
264 Sili, Heslop, and Rooney immuno
- Page 277 and 278:
266 Sili, Heslop, and Rooney Fig. 3
- Page 279 and 280:
268 Sili, Heslop, and Rooney Human
- Page 281 and 282:
270 Sili, Heslop, and Rooney CONCLU
- Page 283 and 284:
272 Sili, Heslop, and Rooney 32. Ba
- Page 285 and 286:
274 Sili, Heslop, and Rooney 73. va
- Page 287 and 288:
276 Donta no controlled clinical tr
- Page 289 and 290:
278 Donta antibody preparation (HA-
- Page 291 and 292:
280 Donta 16. Salcedo J, Keates S,
- Page 294 and 295:
INTRODUCTION From: Immunotherapy fo
- Page 296 and 297:
Tuberculosis and Other Mycobacteria
- Page 298 and 299:
Tuberculosis and Other Mycobacteria
- Page 300 and 301:
Tuberculosis and Other Mycobacteria
- Page 302 and 303:
Tuberculosis and Other Mycobacteria
- Page 304 and 305:
Tuberculosis and Other Mycobacteria
- Page 306 and 307:
Tuberculosis and Other Mycobacteria
- Page 308 and 309:
Tuberculosis and Other Mycobacteria
- Page 310 and 311:
Tuberculosis and Other Mycobacteria
- Page 312 and 313:
Tuberculosis and Other Mycobacteria
- Page 314 and 315:
From: Immunotherapy for Infectious
- Page 316 and 317:
Fungal Infections 305 Table 2 Categ
- Page 318 and 319:
Fungal Infections 307 rapid bone ma
- Page 320 and 321:
Fungal Infections 309 has activity
- Page 322 and 323:
311 Table 4 Case Reports of Unusual
- Page 324 and 325:
Fungal Infections 313 randomized co
- Page 326 and 327:
Fungal Infections 315 the administr
- Page 328 and 329:
Fungal Infections 317 modalities in
- Page 330 and 331:
Fungal Infections 319 35. Vecchiare
- Page 332 and 333:
Fungal Infections 321 74. Han Y, Cu
- Page 334 and 335:
Index 323 A ADCC, see Antibody-depe
- Page 336 and 337:
Index 325 immunotherapy clinical tr
- Page 338 and 339:
Index 327 function, 32, 33, 182-185
- Page 340 and 341:
Index 329 secretory immunoglobulin
- Page 342 and 343:
Index 331 dendritic cell response,